MR‐proADM as a Prognostic Marker in Patients With ST‐Segment–Elevation Myocardial Infarction—DANAMI‐3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy

BACKGROUND: Midregional proadrenomedullin (MR‐proADM) has demonstrated prognostic potential after myocardial infarction (MI). Yet, the prognostic value of MR‐proADM at admission has not been examined in patients with ST‐segment–elevation MI (STEMI). METHODS AND RESULTS: The aim of this substudy, DAN...

Descripción completa

Detalles Bibliográficos
Autores principales: Falkentoft, Alexander C., Rørth, Rasmus, Iversen, Kasper, Høfsten, Dan E., Kelbæk, Henning, Holmvang, Lene, Frydland, Martin, Schoos, Mikkel M., Helqvist, Steffen, Axelsson, Anna, Clemmensen, Peter, Jørgensen, Erik, Saunamäki, Kari, Tilsted, Hans‐Henrik, Pedersen, Frants, Torp‐Pedersen, Christian, Kofoed, Klaus F., Goetze, Jens P., Engstrøm, Thomas, Køber, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015359/
https://www.ncbi.nlm.nih.gov/pubmed/29776961
http://dx.doi.org/10.1161/JAHA.117.008123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015359/
https://www.ncbi.nlm.nih.gov/pubmed/29776961
http://dx.doi.org/10.1161/JAHA.117.008123

Ejemplares similares